Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,086 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation.
Blum W, Bolwell BJ, Phillips G, Farag SS, Lin TS, Avalos BR, Penza SL, Marcucci G, Byrd JC, Kalaycio ME, Sobecks RM, Pohlman B, Brown S, Elder PJ, Copelan EA. Blum W, et al. Among authors: brown s. Biol Blood Marrow Transplant. 2006 Jan;12(1):61-7. doi: 10.1016/j.bbmt.2005.06.004. Biol Blood Marrow Transplant. 2006. PMID: 16399569 Free article.
Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors.
Sobecks RM, Ball EJ, Maciejewski JP, Rybicki LA, Brown S, Kalaycio M, Pohlman B, Andresen S, Theil KS, Dean R, Bolwell BJ. Sobecks RM, et al. Among authors: brown s. Bone Marrow Transplant. 2007 Apr;39(7):417-24. doi: 10.1038/sj.bmt.1705609. Epub 2007 Feb 19. Bone Marrow Transplant. 2007. PMID: 17310134
Influence of killer immunoglobulin-like receptor/HLA ligand matching on achievement of T-cell complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Sobecks RM, Ball EJ, Askar M, Theil KS, Rybicki LA, Thomas D, Brown S, Kalaycio M, Andresen S, Pohlman B, Dean R, Sweetenham J, Macklis R, Bernhard L, Cherni K, Copelan E, Maciejewski JP, Bolwell BJ. Sobecks RM, et al. Among authors: brown s. Bone Marrow Transplant. 2008 Apr;41(8):709-14. doi: 10.1038/sj.bmt.1705954. Epub 2008 Jan 14. Bone Marrow Transplant. 2008. PMID: 18195688
Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial.
Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A. Solomon SR, et al. Among authors: brown s. Biol Blood Marrow Transplant. 2012 Dec;18(12):1859-66. doi: 10.1016/j.bbmt.2012.06.019. Epub 2012 Aug 1. Biol Blood Marrow Transplant. 2012. PMID: 22863841 Free article. Clinical Trial.
Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial.
Solomon SR, Sizemore CA, Zhang X, Brown S, Holland HK, Morris LE, Bashey A. Solomon SR, et al. Among authors: brown s. Bone Marrow Transplant. 2014 May;49(5):616-21. doi: 10.1038/bmt.2014.2. Bone Marrow Transplant. 2014. PMID: 24801098 Clinical Trial.
13,086 results
You have reached the last available page of results. Please see the User Guide for more information.